After a banner year in 2021, Pfizer (NYSE:PFE) is on a spending spree. The company plans to acquire Global Blood Therapeutics (GBT) (Nasdaq:GBT) for $68.50 per share. The total sale price of acquisition, if it moves forward, would be roughly $5.4 billion. Global Blood Therapeutics’s therapeutic focus is primarily on sickle cell disease. In March,…
Pfizer and BioNTech seek EMA authorization for COVID-19 vaccination in young children
Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq: BNTX) have filed paperwork with the European Medicines Agency (EMA) requesting permission to use the Comirnaty COVID-19 vaccine in children aged 6 months to 5 years old. As in the U.S., the companies are attempting to win authorization for a 3-µg dose vaccine administered as a three-dose series.…
Touchlight inks patent license deal with Pfizer related to the use of dbDNA in mRNA products
Touchlight, a British biotech focused on enzymatic DNA production, has announced signing a non-exclusive patent license agreement with Pfizer. The worldwide deal will give Pfizer rights to Touchlight’s enzymatic doggybone DNA (dbDNA) patent portfolio for use in manufacture and commercialization of mRNA-based vaccines, therapeutics and gene therapies. dbDNA is a synthetic DNA vector and enzymatic…
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
The voluntary Net-Zero Standard asks organizations to reduce emissions to near-zero levels by 2050 and neutralize any residual emissions. Pfizer (NYSE:PFE) has announced its intent to meet that benchmark by 2040. Pfizer intends to reduce its Greenhouse Gas (GHG) emissions by 95% and its value chain emissions by 90% from 2019 levels by 2040. To…
Will COVID-19 vaccines be updated by fall?
FDA advisors are slated to meet to discuss the prospect of updating the first generation of COVID-19 vaccines for use as boosters this fall and winter. But it remains unclear whether updating the COVID-19 vaccines will be necessary. Both Pfizer (NYSE:PFE) and Moderna (Nasdaq:MRNA) have updated vaccines in the works. Pfizer and Moderna have both said…
Young children in U.S. now eligible for COVID-19 vaccination
Some 18 months after adults became eligible for COVID-19 vaccines, children between 6 months and 5 years old can now be vaccinated in the U.S. FDA authorized the shots for young children on June 17, while CDC did so a day later. “The United States is now the first country in the world to offer safe…
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Pfizer (NYSE: PFE) announced today that it will invest $120 million into its Kalamazoo, Michigan facility to support U.S.-based production of its COVID-19 antiviral Paxlovid (nirmatrelvir/ritonavir). The investment is expected to create more than 250 additional, high-skilled jobs at the Kalamazoo site. The money will expand the production of active pharmaceutical ingredient (API) and registered…
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
Pfizer (NYSE:PFE) and BioNTech (Nasdaq:BNTX) announced today that data support a three-dose primary series of their COVID-19 vaccine in young children. Topline safety, immunogenicity and vaccine efficacy data from a Phase 2/3 trial in young children evaluating a third 3-µg dose of the vaccine — marketed in the U.S. as Comirnaty — showed a strong…
Pfizer to shell out $11.6B for migraine drugmaker Biohaven
Pfizer (NYSE:PFE) today announced that it has entered into an agreement to acquire Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), which is best known for Nurtec ODT (rimegepant), a dual-acting migraine therapy. Pfizer will pay $148.50 per share in cash to acquire Biohaven, totaling approximately $11.6 billion. Nurtec generated $462 million in revenue in 2021. Pfizer…
Pfizer ticks up on Street-beating Q1, lessens full-year guidance
Pfizer (NYSE:PFE) shares rose today on first-quarter financial results that came in ahead of the consensus forecast. The New York-based pharmaceutical company posted profits of $7.9 billion, or $1.37 per share, on sales of $25.7 billion for the three months ended April 3, 2022, for a 61.2% bottom-line gain on sales growth of 76.8%. Adjusted…